<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04800458</url>
  </required_header>
  <id_info>
    <org_study_id>CHUBX 2020/61</org_study_id>
    <nct_id>NCT04800458</nct_id>
  </id_info>
  <brief_title>Contribution of Anti-platelet Antibodies Identified With MAIPA Assay in the Demonstration of the Auto-immune Character of a Thrombocytopenia at Diagnosis</brief_title>
  <acronym>APAT</acronym>
  <official_title>Contribution of Anti-platelet Antibodies Identified With&quot; Monoclonal Antibody Immobilization of Platelet Antigens&quot; Assay (MAIPA) in the Demonstration of the Auto-immune Character of a Thrombocytopenia at Diagnosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry for Health and Solidarity, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Immune thrombocytopenia (ITP) is an autoimmune disease but, paradoxically, and unlike other&#xD;
      autoimmune diseases, antiplatelet antibodies are not used either for the diagnosis of the&#xD;
      disease or for its prognosis. ITP is a diagnosis of exclusion retained after elimination of&#xD;
      other pathologies leading to a thrombocytopenia. No major study has prospectively evaluated&#xD;
      the diagnostic value of the presence of anti-platelet antibodies in the etiological&#xD;
      investigation of a thrombocytopenia, nor the impact of platelet antibodies on the course of&#xD;
      ITP. The gold standard analysis for the determination of platelet antibodies, is the&#xD;
      &quot;monoclonal antibody immobilization of platelet antigens&quot; assay (MAIPA), either direct to&#xD;
      detect autoantibodies attached to platelets, or indirect to detect circulating antiplatelet&#xD;
      antibodies. Therefore, this work aims to study the contribution of the presence of&#xD;
      anti-platelet antibodies detected in MAIPA to determine the autoimmune nature of a&#xD;
      thrombocytopenia at diagnosis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 19, 2021</start_date>
  <completion_date type="Anticipated">May 2025</completion_date>
  <primary_completion_date type="Anticipated">May 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients with a diagnosis of autoimmune thrombocytopenia among those in whom will be identified anti-platelet antibodies in direct and indirect MAIPA</measure>
    <time_frame>12 months after baseline</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with chronic ITP</measure>
    <time_frame>12 months after baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum Thrombopoietin concentration</measure>
    <time_frame>At baseline and 12 months after baseline</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">225</enrollment>
  <condition>Thrombocytopenia</condition>
  <condition>Immune Thrombocytopenia</condition>
  <condition>Myelodysplasia</condition>
  <arm_group>
    <arm_group_label>thrombocytopenic patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Blood samples</intervention_name>
    <description>If the platelet count is &gt; 20 G / L : 50 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation If the platelet count is &lt; 20 G / L : 30 ml whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation</description>
    <arm_group_label>thrombocytopenic patients</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient over 18 years old;&#xD;
&#xD;
          -  Patients with thrombocytopenia &lt;100 G/L, checked twice, having ruled out false&#xD;
             thrombocytopenia by platelet aggregation and acute leukemia by smear;&#xD;
&#xD;
          -  No treatment started;&#xD;
&#xD;
          -  Free, informed and written consent signed by the participant and the investigator (no&#xD;
             later than the day of inclusion and prior to any review required by the research);&#xD;
&#xD;
          -  Person affiliated or benefiting from a social security scheme.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Secondary ITP;&#xD;
&#xD;
          -  False thrombocytopenia;&#xD;
&#xD;
          -  Patients who have been transfused with platelets (&lt;10 days);&#xD;
&#xD;
          -  Patient with acute leukemia;&#xD;
&#xD;
          -  Pregnant or breastfeeding woman;&#xD;
&#xD;
          -  False thrombocytopenia;&#xD;
&#xD;
          -  Patient under guardianship, curatorship or any other legal protection regime.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-François VIALLARD, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU Bordeaux</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jean-François VIALLARD, Prof</last_name>
    <phone>05.57.65.64.83</phone>
    <phone_ext>+33</phone_ext>
    <email>jean-françois.viallard@chu-bordeaux.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU de Bordeaux - service de médecine interne</name>
      <address>
        <city>Pessac</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean-François VIALLARD, Prof</last_name>
      <phone>05.57.65.64.83</phone>
      <phone_ext>+33</phone_ext>
      <email>jean-françois.viallard@chu-bordeaux.fr</email>
    </contact>
    <investigator>
      <last_name>Jean-François VIALLARD, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Pierre DUFFAU, Prof</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Sophie DIMICOLI-SALAZAR, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>March 11, 2021</study_first_submitted>
  <study_first_submitted_qc>March 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 16, 2021</study_first_posted>
  <last_update_submitted>May 27, 2021</last_update_submitted>
  <last_update_submitted_qc>May 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Monoclonal antibody immobilization of platelet antigens assay</keyword>
  <keyword>MAIPA</keyword>
  <keyword>Anti-platelet antibodies</keyword>
  <keyword>Thrombopoietin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Preleukemia</mesh_term>
    <mesh_term>Thrombocytopenia</mesh_term>
    <mesh_term>Purpura, Thrombocytopenic, Idiopathic</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

